China Resources-affiliated plasma products maker producing albumin and immunoglobulin from donated human plasma.
China Resources-affiliated plasma products maker producing albumin and immunoglobulin from donated human plasma.
Raw plasma collected at licensed donation stations is the scarce input, so the number of stations and the plasma each collects limit output more than sales do; products then go mostly to hospitals through distributors. China Resources, a state-owned group, is the controlling shareholder.
In one line: A Chinese CSL Behring/Grifols.
Moat: narrow (regulatory licence, scale). Plasma-collection licences and blood-product manufacturing approvals are tightly state-regulated and slow to obtain.
Headquarters: Guangzhou, China · Employees: 1,947
Size China Resources Boya Bio-pharmaceutical (300294.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $959M, the 2232nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥13.02 on 18 Nov 2026.
Performance Over six months the shares fell 20.9%, against -12.1% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue fell 27.1% over the last twelve months (peer median +9.8%); the operating margin is -18.7% (peer median 12.6%).
Valuation It trades at 21.4× forward earnings against a peer median of 23.7× (6th cheapest of 13).
Capital Return on invested capital runs 8.9 points below its cost of capital (6.4% WACC).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.43B | CN¥2.05B | CN¥1.73B | CN¥2.64B | CN¥2.75B |
| Revenue growth | — | +19% | -35% | -4% | — |
| Gross profit | CN¥649M | CN¥937M | CN¥1.06B | CN¥1.33B | CN¥1.44B |
| EBITDA | n/a | CN¥434M | CN¥539M | CN¥642M | CN¥619M |
| Net income | -CN¥168M | CN¥113M | CN¥397M | CN¥237M | CN¥432M |
| Free cash flow | -CN¥445M | -CN¥419M | CN¥193M | CN¥653M | CN¥533M |
| Capital expenditure | CN¥472M | CN¥535M | CN¥198M | CN¥87.5M | CN¥138M |
| Total debt | CN¥167M | CN¥333M | CN¥220M | CN¥74.2M | CN¥68.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China Resources Boya Bio-pharmaceutical 300294.SZ | $959M | -21% | -27% | -19% | 21.4× | n/a |
| Shanghai RAAS Blood Products 002252.SZ | $4.57B | -15% | -22% | 17% | 12.8× | n/a |
| CSL CSL.AX | $63.7B | +102% | -2% | 26% | 21.5× | 6.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300294.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.3% | -9.1% | 10th highest of 21 |
| 6-month return | -20.9% | -12.1% | 8th lowest of 21 |
| Distance from 52-week high | -49.2% | -41.9% | 8th lowest of 21 |
| Revenue growth (TTM) | -27.1% | +9.8% | 4th lowest of 19 |
| Operating margin | -18.7% | 12.6% | 4th lowest of 19 |
| Forward P/E | 21.4× | 23.7× | 6th cheapest of 13 |
| ROIC minus cost of capital | -8.9 pp | -0.6 pp | 4th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 21.4× | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 12.5× | 2.3% | -0.5% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 15.9× | 17.6% | +7.8% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 42.3× | 11.6% | +4.9% |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | n/a | 7.7% | -6.9% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | n/a | 10.3% | -13.7% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | n/a | n/a | n/a |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 50.2× | -10.2% | +18.1% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 22.9× | 9.1% | +13.4% |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 9.8× | -3.7% | +13.8% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |